Neurizon Therapeutics Limited · ASX:NUZ
Neurizon Therapeutics — PharmAust — Non-Deal Roadshow (May 2023)
15 slides from Neurizon Therapeutics's roadshow presentation, May 2023
Slide 1: PharmAust Limited
PHARMAUST LIMITED ASX : PAA ACN 094 006 023
Slide 2: Global view of PharmAust
o Ce ntra l o Cos ts re g ula tor of o Sa fety m e ta b olis m o Toxicolog y a nd g row th Pha rm a ceutica l o New Pa tents o Se ve ra l Repurpos ing of MPL m TOR ta rg e ts Monepa ntel Global view of PharmAust o Ha lfw a y MPL a lmos t o B-Ce ll throug h Motor Neurone triples Media n Lym p hom a P
Slide 3: Why MPL? Lead drug candidate
Lead drug candidate WHY MPL? o Drug already registered in 38 countries & APVMA approved o Substantial time and cost savings o Very low toxicity provides a significant advantage over existing mTOR antagonists for the treatment of oncological and neurodegenerative diseases o Crosses Blood-Brain barrie
Slide 4: Slide 4
Slide 5: What is MND?
MPL WHAT IS MND? o Group of progressive neurological disorders o Attack s the motor neurones that control skeletal muscle activity such as walking, breathing, speaking and swallowing o As muscles are unable to receive signals, muscle weakness and wasting becomes widespread o Diseases includes amyotr
Slide 6: ALS/MND addressable market is US$3.6bn
ALS/MND addressable market is The first approved drug US$3.6bn treatment, called Riluzole, became available in 1995 and is believed to extend survival by only 3 -4 months, with many side effects. Despite this, Riluzole is already reaching ~US$1Bn annual sales
Slide 7: FightMND
MPL FightMND o Australia’s largest MND charity, reviewed properties of MPL and its performance in cancer, and awarded PharmAust $880,000 to clinically evaluate MPL in MND progression o PharmAust expects that MPL will be an antagonist to mTOR and slow down the production of misfolded proteins and hen
Slide 8: MND Trial Progressing
Results so far MND Trial Progressing o All 12 patients for Cohorts 1 and 2 have been recruited o Interim analysis recommended by the Principal Investigator – results expected in May o First patient remains stable after 6 months on MPL o In conjunction with Macquarie University, NSW & Calvary Health
Slide 9: Canine Cancer Trial: B-Cell Lymphoma
CANINE CANCER TRIAL B-Cell Lymphoma Current options: FEEDBACK FROM o Early euthanasia of the animal (usually within eight weeks from OWNERS diagnosis) Achieving stable disease for up o Chemotherapy (CHOP) to eight months with good o AEs such as vomiting, diarrhea and restriction of pet contact due t
Slide 10: Typical Survival Periods
TYPICAL SURVIVAL PERIODS Prednisolone* Median Survival (60 days) MPL + Prednisolone** Med ia n Surviva l 1 4 7 d a ys w ith s ta b le Excellent Quality of Life d is ea s e ob s erved Chemotherapy (CHOP)*** Med ia n Surviva l (3 4 5 d a ys ) Typical Chemotherapy Side-Effects and $10k+
Slide 11: Decision process of Chemotherapy vs Monepantel
Chemotherapy Monepantel Decision process of Chemotherapy vs Monepantel
Slide 12: Veterinary cancer market and licensing
o ~6 million new cancer Corporate outcom diagnoses are made A licensing deal in US dogs every year * would mark a o Now engaging with Global significant Veterinary Companies for commercial licensing outcome and support funding for future clinical trials * - https://www.aaha.org/your -pet/pet -owner
Slide 13: Why Human Cancer?
MPL WHY HUMAN CANCER? o Strong data from the aggressive B -Cell Lymphoma cancer trial in canines suggests Abraxane market positive correlation/translation for targeting multiple cancers in humans size to hit over o During 2023 PharmAust will examine the US$11.16 billion by value of MPL in at least o
Slide 14: Upcoming Catalysts
UPCOMING CATALYSTS o Completion and results from fully funded Phase 1/2 - Hum a n MND tria l. Inte rim re s ults e xpe cte d in Ma y o Initia l s a fe ty & PK da ta from Pha s e 1 MND tria ls to fa s t tra ck Pha s e 2 hum a n a nti-ca nce r o Pha s e 2 ve t ca nce r tria l to be com ple te d m id 2
Slide 15: For more info visit
For more info visit www.pharmaust.com